Leerink raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $525 from $456 and keeps an Outperform rating on the shares. The firm cites an increase in its terminal growth assumption from 1% to 2%. Leerink is optimistic about the company’s revenue and pipeline prospects, which it expects to drive stock price performance. The firm would caveat that it projects higher investment spending growth than consensus models.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRTX:
finance.yahoo.com
#Vertex #Pharmaceuticals #price #target #raised #Leerink
